Back to top
more

HeartBeam (BEAT)

(Delayed Data from NSDQ)

$2.05 USD

2.05
13,855

+0.01 (0.49%)

Updated Apr 24, 2024 03:59 PM ET

After-Market: $2.05 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Philips (PHG) Expands Portfolio With BioTelemetry Acquisition

Philips (PHG) enters into a deal to acquire BioTelemetry, which drives the expansion of its cardiac care portfolio and fuels customer acquisition.

BioTelemetry (BEAT) Q3 Earnings and Revenues Beat Estimates

BioTelemetry (BEAT) delivered earnings and revenue surprises of 15.38% and 7.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) Looks Good: Stock Adds 7.7% in Session

BioTelemetry (BEAT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

BioTelemetry (BEAT) Beats Q2 Earnings and Revenue Estimates

BioTelemetry (BEAT) delivered earnings and revenue surprises of 191.67% and 15.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for BioTelemetry (BEAT) This Earnings Season?

BioTelemetry (BEAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BioTelemetry (BEAT) to Report Q1 Results: Wall Street Expects Earnings Growth

BioTelemetry (BEAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioTelemetry (BEAT) Q4 Earnings Meet Estimates

BioTelemetry (BEAT) delivered earnings and revenue surprises of 0.00% and 1.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) Beats Q3 Earnings and Revenue Estimates

BioTelemetry (BEAT) delivered earnings and revenue surprises of 4.00% and 0.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) Q2 Earnings and Revenues Beat Estimates

BioTelemetry (BEAT) delivered earnings and revenue surprises of 17.78% and 0.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate BioTelemetry (BEAT) to Report a Decline in Earnings: What to Look Out for

BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioTelemetry (BEAT) to Report Q2 Earnings: What's in Store?

BioTelemetry's (BEAT) strong second-quarter 2019 expectations are indicative of solid results.

Analysts Estimate BioTelemetry (BEAT) to Report a Decline in Earnings: What to Look Out for

BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know

BioTelemetry (BEAT) closed the most recent trading day at $47.69, moving +1.6% from the previous trading session.

BioTelemetry (BEAT) to Report Q1 Earnings: What's in Store?

Products like MCT and Ware Holter are likely to aid BioTelemetry (BEAT) in Q1.

Kevin Cook headshot

Bull of the Day: BioTelemetry (BEAT)

Medical research partner to Apple in large cardiac monitoring study, this serial earnings surpriser just went on sale

Panel Of Zacks Experts headshot

Top Stock Picks for the Week of Apr 22, 2019

Tracey Ryniec and Kevin Cook look at two highly rated stocks.

BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, BioTelemetry (BEAT) closed at $55.13, marking a +0.35% move from the previous day.

BioTelemetry (BEAT) Earnings Expected to Grow: Should You Buy?

BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teladoc's Partnership to Form Pediatric Telehealth Platform

Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.

Has BioTelemetry (BEAT) Outpaced Other Medical Stocks This Year?

Is (BEAT) Outperforming Other Medical Stocks This Year?

BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, BioTelemetry (BEAT) closed at $60.03, marking a -0.94% move from the previous day.

BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, BioTelemetry (BEAT) closed at $62.11, marking a +0.57% move from the previous day.

BioTelemetry (BEAT) Gains But Lags Market: What You Should Know

BioTelemetry (BEAT) closed the most recent trading day at $68.46, moving +0.87% from the previous trading session.

Teladoc to Acquire MedecinDirect, Expand Overseas Business

Teladoc's (TDOC) acquisition of MedecinDirect will aid it in enhancing presence in expanding virtual care market in France.

Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?

Is (BEAT) Outperforming Other Medical Stocks This Year?